The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas.
 
Robert Hsu
No Relationships to Disclose
 
Yasmine Baca
No Relationships to Disclose
 
Joanne Xiu
Employment - Caris Life Sciences
 
Rongfu Wang
No Relationships to Disclose
 
Joseph Nicholas Bodor
No Relationships to Disclose
 
Chul Kim
Consulting or Advisory Role - Janssen; Novartis
Research Funding - AstraZeneca; Bristol-Myers Squibb; Debiopharm Group; Karyopharm Therapeutics; Novartis; Regeneron; Tesaro
 
Hina Khan
No Relationships to Disclose
 
Hirva Mamdani
Consulting or Advisory Role - AstraZeneca; Zentalis
Travel, Accommodations, Expenses - AstraZeneca; Caris Life Sciences; Takeda
 
Misako Nagasaka
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Novartis; Takeda
Speakers' Bureau - Blueprint Medicines
Research Funding - Tempus
Travel, Accommodations, Expenses - Anheart Therapeutics
 
Sonam Puri
Consulting or Advisory Role - AstraZeneca (Inst); G1 Therapeutics (Inst)
 
Stephen V. Liu
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Blueprint Medicines; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; G1 Therapeutics; Genentech; Guardant Health; Inivata; Janssen Oncology; Jazz Pharmaceuticals; Lilly; MSD Oncology; Pfizer; PharmaMar; Regeneron; Takeda
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Debiopharm Group (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Lilly (Inst); Lycera (Inst); Merck (Inst); Merus (Inst); Molecular Partners (Inst); Pfizer (Inst); Rain Therapeutics (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Roche/Genentech
 
Wolfgang Michael Korn
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Consulting or Advisory Role - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Jorge J. Nieva
Stock and Other Ownership Interests - Cansera; Epic Sciences; Indee P/L; Quantgene
Consulting or Advisory Role - AstraZeneca; Fujirebio Diagnostics; Naveris
Research Funding - Merck
Patents, Royalties, Other Intellectual Property - Patent Pending - movement and unexpected healthcare encounters